Healthcare
Ultragenyx Pharmaceutical Inc.(RARE)
Live Price
Offline$27.44
+1.97% today
1Y Change
-33.89%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $2.44B
- Revenue Growth
- +20.1%
- EPS Growth
- +7.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ultragenyx Pharmaceutical Inc. (RARE) is a Healthcare stock with a market cap of $2.44B and listed on NASDAQ. The stock last traded around $27.44 and down 33.9% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +20.1%, EPS growth of +7.3%, a dividend yield of 0.0%. What stands out right now is revenue +20.1%, EPS +7.3%, free cash flow -11.9% with operating margin -79.6% and ROIC -43.6%. Valuation is more restrained than many high-expectation growth names at price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RARE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.1% vs +7.6% peer median
Operating Margin
Below sector median
-79.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.1% and EPS at +7.3%, with operating margin around -79.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +3.7% | +7.3% | -10.4% |
2026 Feb 12, 2026 | -7.5% | -12.7% | -3.3% | -9.2% |
2025 Nov 4, 2025 | -47.1% | -1.8% | +2.4% | +12.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RARE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RARE Max Drawdown
-55.36%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RARE and SPY.
Company Overview
Ultragenyx Pharmaceutical Inc.
NASDAQ Global Select
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
- Leadership
- Emil D. Kakkis
- IPO Date
- Jan 31, 2014
- Employees
- 1.3k
- Street Address
- 60 Leveroni Court
- Mailing
- Novato, CA, 94949
- Region
- Novato, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 483 8800
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.6
- Price/Book
- โ
Growth
- Revenue
- +20.1%
- EPS
- +7.3%
- Free Cash Flow
- -11.9%
Profitability
- Gross Margin
- 83.8%
- Operating Margin
- -79.6%
- Net Margin
- -85.5%
- ROE
- -1024.4%
- ROIC
- -43.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.48
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.